Publication:
Why is the Safety of Medicines Important for Resilient Health Systems? A Synthesis Report

Simple item page
dc.contributor.authorWang, Huihui
dc.contributor.authorMarquez, Patricio V.
dc.contributor.authorFigueras, Albert
dc.contributor.authorBieliaieva, Kseniya
dc.date.accessioned2023-08-22T16:59:12Z
dc.date.available2023-08-22T16:59:12Z
dc.date.issued2023-08-22
dc.description.abstractThis report discusses the importance of pharmacovigilance (PV) in contributing to building up resilient health systems. It is based on and summarizes the findings of a review of available literature on the topic and relevant case studies focusing on a set of country and regional experiences. Although indispensable in improving health outcomes, the administration and use of medicines may produce adverse reactions, requiring continuous monitoring to ensure that the benefits outweigh the risks. PV, which involves the systematic detection, reporting, assessment, understanding, and prevention of adverse drug reactions (ADRs), is an essential public health function, but it is often overlooked. The review suggests that successful PV programs are built on three essential pillars: statutory provisions that establish standards for PV centers and programs, well-trained health professionals and associated stakeholders, and engaged PV reporters using effective reporting systems. These pillars allow PV programs to be effective in three core activities: reporting adverse drug events (ADEs) and identifying signals, determining threats through a benefit-risk balance analysis, and taking appropriate actions. This is in addition to supporting various functions of a health system, such as national drug policy and regulation, the delivery of medical care, specific disease control programs, increasing the trust of the general public in the system, and promoting eco-PV. Aided by emerging opportunities for development through automation and machine learning, PV programs show immense potential to enhance the monitoring of patient safety and improve the use of medicines. The report offers policy considerations for countries and international partners in building PV capacity as an essential public function of a health system.en
dc.identifierhttp://documents.worldbank.org/curated/en/099855108172335548/IDU090d1be4d0188f040e108dc303d5bff302fa1
dc.identifier.doi10.1596/40247
dc.identifier.urihttps://openknowledge.worldbank.org/handle/10986/40247
dc.languageEnglish
dc.language.isoen_US
dc.publisherWashington, DC: World Bank
dc.relation.ispartofseriesPharmacovigilance and Essential Public Health Services Series
dc.rightsCC BY-NC 3.0 IGO
dc.rights.holderWorld Bank
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/igo
dc.subjectPHARMACOVIGILANCE
dc.subjectRESILIENT HEALTH SYSTEMS
dc.subjectDRUG SAFETY
dc.subjectPV
dc.subjectTHALIDOMIDE TRAGEDY
dc.subjectCOVID-19 LESSONS
dc.titleWhy is the Safety of Medicines Important for Resilient Health Systems? A Synthesis Reporten
dc.typeReport
dspace.entity.typePublication
okr.crossref.titleWhy is the Safety of Medicines Important for Resilient Health Systems? A Synthesis Report
okr.date.disclosure2023-08-22
okr.date.doiregistration2025-04-07T08:57:10.453283Z
okr.date.doiregistration2025-04-08T16:29:12.878616Z
okr.date.doiregistration2025-04-09T03:06:44.690263Z
okr.date.lastmodified2023-08-21T00:00:00Zen
okr.doctypeEconomic & Sector Work
okr.doctypeEconomic & Sector Work::Other Health Study
okr.docurlhttp://documents.worldbank.org/curated/en/099855108172335548/IDU090d1be4d0188f040e108dc303d5bff302fa1
okr.guid099855108172335548
okr.identifier.docmidIDU-90d1be4d-188f-40e1-8dc3-3d5bff302fa1
okr.identifier.doihttp://dx.doi.org/10.1596/40247
okr.identifier.externaldocumentum34145252
okr.identifier.internaldocumentum34145252
okr.identifier.report184551
okr.import.id1559
okr.importedtrueen
okr.language.supporteden
okr.pdfurlhttp://documents.worldbank.org/curated/en/099855108172335548/pdf/IDU090d1be4d0188f040e108dc303d5bff302fa1.pdfen
okr.region.geographicalWorld
okr.sectorHealth-HG
okr.themeHealth Systems and Policies,Human Development and Gender,Private Sector Delivery in Health,Reproductive and Maternal Health,Health Finance,Health Service Delivery,Health System Strengthening,Child Health,Adolescent Health,Health Systems and Policies,Human Development and Gender,Disease Control,Health System Strengthening,Pandemic Response,Health Service Delivery
okr.topicHealth, Nutrition and Population::Pharmaceuticals & Pharmacoeconomics
okr.topicHealth, Nutrition and Population::Health Monitoring & Evaluation
okr.topicHealth, Nutrition and Population::Health Systems Development & Reform
okr.unitHNP Global (HHNGE)
relation.isAuthorOfPublication601b45de-9e7b-5045-bfef-0689612779d8
relation.isAuthorOfPublication.latestForDiscovery601b45de-9e7b-5045-bfef-0689612779d8
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
IDU090d1be4d0188f040e108dc303d5bff302fa1.pdf
Size:
493.64 KB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
IDU090d1be4d0188f040e108dc303d5bff302fa1.txt
Size:
150.74 KB
Format:
Plain Text
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download
Collections
Other Health Study